Boehringer Ingelheim signs £574m deal for Lupin’s MEK inhibitor compound
The partnership between Boehringer Ingelheim and Lupin will develop LNP3794 as a potential targeted therapy for patients with difficult-to-treat cancers. The companies will develop the MEK inhibitor compound